How the CMO of Sage Therapeutics Positioned a New Indication for FDA Approval

from PharmaTalkRadio · host Conference Forum

In this session recorded at the 7th annual Chief Medical Officer Summit, Dr Steve Kanes, Chief Medical Officer, Sage Therapeutics, discusses how a company considered as an "up and comer" in the Cambridge biotech sector navigated the development and approval of the first treatment specifically designed for postpartum depression. Learn more at theconferenceforum.org

Episode metadata supplied by the publisher feed · Published Dec 2, 2019

Embed this episode

Attribution link and audio player

Ready to play

How the CMO of Sage Therapeutics Positioned a New Indication for FDA Approval

0:00 36:39

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of PharmaTalkRadio?

This episode is 36 minutes long.

When was this PharmaTalkRadio episode published?

This episode was published on December 2, 2019.

Can I download this PharmaTalkRadio episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!